Stomach antral endocrine cells in patients with irritable bowel syndrome

El-Salhy,Magdy; Gilja,Odd  Helge; Hatlebakk,Jan  Gunnar; Hausken,Trygve

doi:10.3892/ijmm.2014.1887

Stomach antral endocrine cells in patients with irritable bowel syndrome

Authors:
- Magdy El-Salhy
- Odd Helge Gilja
- Jan Gunnar Hatlebakk
- Trygve Hausken
View Affiliations

Affiliations: Division of Gastroenterology, Department of Medicine, Stord Helse-Fonna Hospital, Stord, Norway, Division of Gastroenterology, Department of Clinical Medicine, University of Bergen, Bergen, Norway
Published online on: August 8, 2014 https://doi.org/10.3892/ijmm.2014.1887
Pages: 967-974
Copyright: © El-Salhy et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY_NC 3.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

To the best of our knowledge, stomach antral endocrine cells have not previously been investigated in patients with irritable bowel syndrome (IBS). Thus, in the present study, 76 patients with IBS were examined (designated as IBS-total). Diarrhoea was the predominant symptom in 26 of these patients (IBS-D), while in 21 patients, the predominant symptoms were both diarrhoea and constipation (IBS-M) and in 29 patients the predominant symptom was constipation (IBS-C). Forty-three healthy subjects were enrolled as the controls. Stomach antral biopsy samples obtained from all of the subjects were immunostained using the avidin-biotin-complex method for serotonin, gastrin, somatostatin and serotonin transporter (SERT). The immunopositive cell densities and immunoreactivity intensities were determined by computer-aided image analysis. The density of the serotonin-immunoreactive cells was significantly decreased in the IBS-M patients and increased in the IBS-C patients relative to the controls. The immunoreactivity intensity did not differ significantly between the controls and IBS-total. The density of the gastrin-immunoreactive cells was significantly greater in the IBS-D, IBS-M and IBS-C patients than in the controls. The immunoreactivity intensity of gastrin was significantly greater in the IBS-D patients than in the controls. The density of the somatostatin-immunoreactive cells cells was significantly lower in the IBS-total, IBS-D, IBS-M and IBS-C patients than in the controls. The immunoreactivity intensities of both somatostatin and SERT did not differ significantly between the controls and IBS-total. The increase in gastrin cell density and the decrease in somatostatin cell density in all IBS subtypes may cause high levels of gastric secretion, which may in turn contribute to the high incidence of dyspepsia and gastro-oesophageal reflux observed in patients with IBS.

View Figures

View References

1	Moran GW, Leslie FC, Levison SE, Worthington J and McLaughlin JT: Enteroendocrine cells: neglected players in gastrointestinal disorders? Therap Adv Gastroenterol. 1:51–60. 2008. View Article : Google Scholar : PubMed/NCBI
2	El-Salhy M, Seim I, Chopin L, Gundersen D, Hatlebakk JG and Hausken T: Irritable bowel syndrome: the role of gut neuroendocrine peptides. Front Biosci (Elite Ed). 4:2783–2800. 2012. View Article : Google Scholar : PubMed/NCBI
3	El-Salhy M, Ostgaard H, Gundersen D, Hatlebakk JG and Hausken T: The role of diet in the pathogenesis and management of irritable bowel syndrome (Review). Int J Mol Med. 29:723–731. 2012.PubMed/NCBI
4	El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T: Irritable bowel syndrome: diagnosis, pathogenesis and treatment options. Nova Science Publishers Inc; New York: 2012
5	Sternini C, Anselmi L and Rozengurt E: Enteroendocrine cells: a site of ‘taste’ in gastrointestinal chemosensing. Curr Opin Endocrinol Diabetes Obes. 15:73–78. 2008.
6	Sternini C: Taste receptors in the gastrointestinal tract. IV. Functional implications of bitter taste receptors in gastrointestinal chemosensing. Am J Physiol Gastrointest Liver Physiol. 292:G457–G461. 2007. View Article : Google Scholar : PubMed/NCBI
7	Raybould HE: Gut chemosensing: interactions between gut endocrine cells and visceral afferents. Auton Neurosci. 153:41–46. 2010. View Article : Google Scholar : PubMed/NCBI
8	Raybould HE: Nutrient sensing in the gastrointestinal tract: possible role for nutrient transporters. J Physiol Biochem. 64:349–356. 2008. View Article : Google Scholar : PubMed/NCBI
9	Bertrand PP and Bertrand RL: Serotonin release and uptake in the gastrointestinal tract. Auton Neurosci. 153:47–57. 2010. View Article : Google Scholar : PubMed/NCBI
10	Akiba Y and Kaunitz JD: Luminal chemosensing in the duodenal mucosa. Acta Physiol (Oxf). 201:77–84. 2011. View Article : Google Scholar : PubMed/NCBI
11	Steinert RE and Beglinger C: Nutrient sensing in the gut: interactions between chemosensory cells, visceral afferents and the secretion of satiation peptides. Physiol Behav. 105:62–70. 2011. View Article : Google Scholar : PubMed/NCBI
12	Nakamura E, Hasumura M, Uneyama H and Torii K: Luminal amino acid-sensing cells in gastric mucosa. Digestion. 83(Suppl 1): 13–18. 2011. View Article : Google Scholar
13	Tolhurst G, Reimann F and Gribble FM: Intestinal sensing of nutrients. Handb Exp Pharmacol. 309–335. 2012. View Article : Google Scholar
14	Mace OJ, Schindler M and Patel S: The regulation of K- and L-cell activity by GLUT2 and the calcium-sensing receptor CasR in rat small intestine. J Physiol. 590:2917–2936. 2012. View Article : Google Scholar : PubMed/NCBI
15	El-Salhy M, Lillebo E, Reinemo A and Salmelid L: Ghrelin in patients with irritable bowel syndrome. Int J Mol Med. 23:703–707. 2009. View Article : Google Scholar : PubMed/NCBI
16	Dizdar V, Spiller R, Singh G, et al: Relative importance of abnormalities of CCK and 5-HT (serotonin) in Giardia-induced post-infectious irritable bowel syndrome and functional dyspepsia. Aliment Pharmacol Ther. 31:883–891. 2010.PubMed/NCBI
17	El-Salhy M, Vaali K, Dizdar V and Hausken T: Abnormal small-intestinal endocrine cells in patients with irritable bowel syndrome. Dig Dis Sci. 55:3508–3513. 2010. View Article : Google Scholar : PubMed/NCBI
18	El-Salhy M, Gundersen D, Ostgaard H, Lomholt-Beck B, Hatlebakk JG and Hausken T: Low densities of serotonin and peptide YY cells in the colon of patients with irritable bowel syndrome. Dig Dis Sci. 57:873–878. 2012. View Article : Google Scholar : PubMed/NCBI
19	El-Salhy M, Gundersen D, Hatlebakk JG and Hausken T: Abnormal rectal endocrine cells in patients with irritable bowel syndrome. Regul Pept. 188:60–65. 2014. View Article : Google Scholar : PubMed/NCBI
20	Coates MD, Mahoney CR, Linden DR, et al: Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology. 126:1657–1664. 2004. View Article : Google Scholar : PubMed/NCBI
21	Wang SH, Dong L, Luo JY, et al: Decreased expression of serotonin in the jejunum and increased numbers of mast cells in the terminal ileum in patients with irritable bowel syndrome. World J Gastroenterol. 13:6041–6047. 2007. View Article : Google Scholar : PubMed/NCBI
22	Lee KJ, Kim YB, Kim JH, Kwon HC, Kim DK and Cho SW: The alteration of enterochromaffin cell, mast cell, and lamina propria T lymphocyte numbers in irritable bowel syndrome and its relationship with psychological factors. J Gastroenterol Hepatol. 23:1689–1694. 2008. View Article : Google Scholar : PubMed/NCBI
23	Park JH, Rhee PL, Kim G, et al: Enteroendocrine cell counts correlate with visceral hypersensitivity in patients with diarrhoea-predominant irritable bowel syndrome. Neurogastroenterol Motil. 18:539–546. 2006. View Article : Google Scholar : PubMed/NCBI
24	Kim HS, Lim JH, Park H and Lee SI: Increased immunoendocrine cells in intestinal mucosa of postinfectious irritable bowel syndrome patients 3 years after acute Shigella infection: an observation in a small case control study. Yonsei Med J. 51:45–51. 2010.PubMed/NCBI
25	Dunlop SP, Coleman NS, Blackshaw E, et al: Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol. 3:349–357. 2005. View Article : Google Scholar : PubMed/NCBI
26	Spiller RC, Jenkins D, Thornley JP, et al: Increased rectal mucosal enteroendocrine cells, T lymphocytes, and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut. 47:804–811. 2000. View Article : Google Scholar : PubMed/NCBI
27	El-Salhy M, Lomholt-Beck B and Hausken T: Chromogranin A as a possible tool in the diagnosis of irritable bowel syndrome. Scand J Gastroenterol. 45:1435–1439. 2010. View Article : Google Scholar : PubMed/NCBI
28	El-Salhy M, Mazzawi T, Gundersen D and Hausken T: Chromogranin A cell density in the rectum of patients with irritable bowel syndrome. Mol Med Rep. 6:1223–1225. 2012.PubMed/NCBI
29	Longstreth GF, Thompson WG, Chey WD, Houghton LA, Mearin F and Spiller RC: Functional bowel disorders. Gastroenterology. 130:1480–1491. 2006. View Article : Google Scholar : PubMed/NCBI
30	Spiller R, Aziz Q, Creed F, et al: Guidelines on the irritable bowel syndrome: mechanisms and practical management. Gut. 56:1770–1798. 2007. View Article : Google Scholar : PubMed/NCBI
31	Roalfe AK, Roberts LM and Wilson S: Evaluation of the Birmingham IBS symptom questionnaire. BMC Gastroenterol. 8:302008. View Article : Google Scholar : PubMed/NCBI
32	Talley NJ, Verlinden M and Jones M: Quality of life in functional dyspepsia: responsiveness of the Nepean Dyspepsia Index and development of a new 10-item short form. Aliment Pharmacol Ther. 15:207–216. 2001. View Article : Google Scholar : PubMed/NCBI
33	Arslan G, Lind R, Olafsson S, Florvaag E and Berstad A: Quality of life in patients with subjective food hypersensitivity: applicability of the 10-item short form of the Nepean Dyspepsia Index. Dig Dis Sci. 49:680–687. 2004. View Article : Google Scholar : PubMed/NCBI
34	Patrick DL, Drossman DA, Frederick IO, DiCesare J and Puder KL: Quality of life in persons with irritable bowel syndrome: development and validation of a new measure. Dig Dis Sci. 43:400–411. 1998. View Article : Google Scholar : PubMed/NCBI
35	Drossman DA, Patrick DL, Whitehead WE, et al: Further validation of the IBS-QOL: a disease-specific quality-of-life questionnaire. Am J Gastroenterol. 95:999–1007. 2000. View Article : Google Scholar : PubMed/NCBI
36	Gershon MD and Tack J: The serotonin signaling system: from basic understanding to drug development for functional GI disorders. Gastroenterology. 132:397–414. 2007. View Article : Google Scholar : PubMed/NCBI
37	Gershon MD: Plasticity in serotonin control mechanisms in the gut. Curr Opin Pharmacol. 3:600–607. 2003. View Article : Google Scholar : PubMed/NCBI
38	Gershon MD: 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 20:14–21. 2013. View Article : Google Scholar : PubMed/NCBI
39	Gershon MD: Serotonin is a sword and a shield of the bowel: serotonin plays offense and defense. Trans Am Clin Climatol Assoc. 123:268–280. 2012.PubMed/NCBI
40	Camilleri M, Andrews CN, Bharucha AE, et al: Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology. 132:17–25. 2007. View Article : Google Scholar : PubMed/NCBI
41	Camilleri M, Busciglio I, Carlson P, et al: Candidate genes and sensory functions in health and irritable bowel syndrome. Am J Physiol Gastrointest Liver Physiol. 295:G219–G225. 2008. View Article : Google Scholar : PubMed/NCBI
42	Kumar S, Ranjan P, Mittal B and Ghoshal UC: Serotonin transporter gene (SLC6A4) polymorphism in patients with irritable bowel syndrome and healthy controls. J Gastrointestin Liver Dis. 21:31–38. 2012.PubMed/NCBI
43	Park JM, Choi MG, Park JA, et al: Serotonin transporter gene polymorphism and irritable bowel syndrome. Neurogastroenterol Motil. 18:995–1000. 2006. View Article : Google Scholar : PubMed/NCBI
44	Saito YA, Locke GR III, Zimmerman JM, et al: A genetic association study of 5-HTT LPR and GNbeta3 C825T polymorphisms with irritable bowel syndrome. Neurogastroenterol Motil. 19:465–470. 2007. View Article : Google Scholar : PubMed/NCBI
45	Wendelbo I, Mazzawi T and El-Salhy M: Increased serotonin transporter immunoreactivity intensity in the ileum of patients with irritable bowel disease. Mol Med Rep. 9:180–184. 2013.PubMed/NCBI
46	El-Salhy M, Wendelbo I and Gundersen D: Serotonin and serotonin transporter in the rectum of patients with irritable bowel disease. Mol Med Rep. 8:451–455. 2013.PubMed/NCBI
47	Schubert ML: Gastric secretion. Curr Opin Gastroenterol. 27:536–542. 2011. View Article : Google Scholar
48	Schubert ML: Gastric secretion. Curr Opin Gastroenterol. 26:598–603. 2010. View Article : Google Scholar
49	Schubert ML: Gastric secretion. Curr Opin Gastroenterol. 23:595–601. 2007. View Article : Google Scholar
50	Schubert ML: Gastric secretion. Curr Opin Gastroenterol. 18:639–649. 2002. View Article : Google Scholar
51	Chu S and Schubert ML: Gastric secretion. Curr Opin Gastroenterol. 28:587–593. 2012. View Article : Google Scholar
52	Van Citters GW and Lin HC: Ileal brake: neuropeptidergic control of intestinal transit. Curr Gastroenterol Rep. 8:367–373. 2006.PubMed/NCBI
53	Pourhoseingholi A, Vahedi M, Pourhoseingholi MA, et al: Irritable bowel syndrome, gastro-oesophageal reflux disease and dyspepsia: overlap analysis using loglinear models. Arab J Gastroenterol. 13:20–23. 2012. View Article : Google Scholar
54	Kim HG, Lee KJ, Lim SG, Jung JY and Cho SW: G-protein beta3 subunit C825T polymorphism in patients with overlap syndrome of functional dyspepsia and irritable Bowel syndrome. J Neurogastroenterol Motil. 18:205–210. 2012. View Article : Google Scholar : PubMed/NCBI
55	Suzuki H and Hibi T: Overlap syndrome of functional dyspepsia and irritable bowel syndrome - are both diseases mutually exclusive? J Neurogastroenterol Motil. 17:360–365. 2011. View Article : Google Scholar : PubMed/NCBI
56	Nakajima S, Takahashi K, Sato J, et al: Spectra of functional gastrointestinal disorders diagnosed by Rome III integrative questionnaire in a Japanese outpatient office and the impact of overlapping. J Gastroenterol Hepatol. 25(Suppl 1): S138–S143. 2010. View Article : Google Scholar
57	Olafsdottir LB, Gudjonsson H, Jonsdottir HH and Thjodleifsson B: Stability of the irritable bowel syndrome and subgroups as measured by three diagnostic criteria - a 10-year follow-up study. Aliment Pharmacol Ther. 32:670–680. 2010.PubMed/NCBI
58	Kaji M, Fujiwara Y, Shiba M, et al: Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol. 25:1151–1156. 2010. View Article : Google Scholar : PubMed/NCBI
59	Noh YW, Jung HK, Kim SE and Jung SA: Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to rome III criteria. J Neurogastroenterol Motil. 16:148–156. 2010. View Article : Google Scholar : PubMed/NCBI
60	Hori K, Matsumoto T and Miwa H: Analysis of the gastrointestinal symptoms of uninvestigated dyspepsia and irritable bowel syndrome. Gut Liver. 3:192–196. 2009. View Article : Google Scholar : PubMed/NCBI
61	Ford AC, Marwaha A, Lim A and Moayyedi P: Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol. 8:401–409. 2010. View Article : Google Scholar : PubMed/NCBI
62	Wang LH, Fang XC and Pan GZ: Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut. 53:1096–1101. 2004. View Article : Google Scholar : PubMed/NCBI
63	Dunlop SP, Jenkins D, Neal KR and Spiller RC: Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology. 125:1651–1659. 2003. View Article : Google Scholar : PubMed/NCBI
64	El-Salhy M, Gundersen D, Gilja OH, Hatlebakk JG and Hausken T: Is irritable bowel syndrome an organic disorder? World J Gastroenterol. 2:384–400. 2014. View Article : Google Scholar
65	El-Salhy M, Hatlebakk JG, Gilja OH and Hausken T: Irritable bowel syndrome: recent developments in diagnosis, pathophysiology, and treatment. Expert Rev Gastroenterol Hepatol. 8:435–443. 2014. View Article : Google Scholar : PubMed/NCBI